Provided by Tiger Trade Technology Pte. Ltd.

INVESCO PHARMACEUTICALS ETF

121.10
+0.22000.18%
Post-market: 121.100.00000.00%19:52 EDT
Volume:41.42K
Turnover:5.01M
Market Cap:546.16M
PE:6.28
High:121.63
Open:120.70
Low:120.17
Close:120.88
52wk High:131.68
52wk Low:92.10
Shares:4.51M
Float Shares:4.51M
Volume Ratio:0.85
T/O Rate:0.92%
Dividend:1.12
Dividend Rate:0.93%
EPS(TTM):19.29
EPS(LYR):21.73
ROE:23.89%
ROA:0.60%
PB:1.64
PE(LYR):5.57

Loading ...

With Approval Looking Likely, How Fast Will Sales of Cancer-Screening Blood Tests Rise?

Dow Jones
·
Sep 23

AbbVie Tells USTR Germany Drug Pricing Reforms Cut Innovative Medicine Value by Nearly 54%

Reuters
·
Sep 23

Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Viking Therapeutics (VKTX) and Amgen (AMGN)

TIPRANKS
·
Sep 22

Amgen Inc Stock (AMGN) Moved Up by 3.90% on Sep 22: Facts Behind the Movement

TradingKey
·
Sep 22

Eli Lilly Price Target Maintained with a $1250.00/Share by TD Cowen

Dow Jones
·
Sep 22

Competitive profile of Amgen’s dazodalibep still ‘open question,’ says Citi

TIPRANKS
·
Sep 22

Dow Falls 134 Points on Losses for Shares of Cisco, JPMorgan Chase

Dow Jones
·
Sep 22

Amgen Rises After Autoimmune Drug Meets Late-Stage Trial Goal

Reuters
·
Sep 22

Viking Therapeutics Stock Surges 35%. It Could Challenge Lilly and Novo's Obesity Empire

Dow Jones
·
Sep 22

Amgen Says Dazodalibep Meets Primary Endpoint in Phase 3 Sjögren's Disease Trial

Reuters
·
Sep 22

Amgen Shares up 3% After Co's Autoimmune Disease Drug Succeeds in Late-Stage Trial

THOMSON REUTERS
·
Sep 22

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pyxis Oncology (PYXS), Moderna (MRNA) and Eli Lilly & Co (LLY)

TIPRANKS
·
Sep 22

Weight-Loss Drug Developers Line up to Tap Lucrative Market as Competition Heats Up

Reuters
·
Sep 22

Amgen Says Phase 3 Trial Shows Dazodalibep Cuts Systemic Disease Activity in Sjögren’s Disease

Reuters
·
Sep 22

Amgen Announces Positive Topline Phase 3 Results for Dazodalibep in Moderate-to-Severe Systemic SjÖGren's Disease

THOMSON REUTERS
·
Sep 22

Viking Therapeutics Surges Nearly 50% Premarket as Once-Every-Two-Week Dosing Retains 97% of Weight Loss

Stock News
·
Sep 22

Amgen: Dazodalibep Showed Statistically Significant & Clinically Meaningful Improvement in Systemic Disease Activity

THOMSON REUTERS
·
Sep 22

Amgen: Phase 3 Oasiz 303 Study of Dazodalibep in Moderate-to-Severe Symptomatic SjÖGren’s Disease Expected to Complete in Q4 2026

THOMSON REUTERS
·
Sep 22

Viking Therapeutics Stock Surges 36%. it Could Challenge Lilly and Novo's Obesity Empire.

Dow Jones
·
Sep 22

DePuy Synthes Showcases Next-Generation Trauma Innovations at OTA 2026

Reuters
·
Sep 22